USP7
Oncology
DiscoveryActive
Key Facts
About Qubit Pharmaceuticals
Qubit Pharmaceuticals is a Paris-based, private biotech firm pioneering a quantum-aided drug discovery platform. The company integrates decades of computational chemistry research into its ATLAS platform, which uses quantum mechanics, AI, and hybrid HPC/quantum computing to generate and simulate novel drug candidates with high precision. With a team of over 60 experts and a pipeline of over 20 programs, Qubit is targeting historically undruggable targets in oncology and inflammation while actively seeking partnerships to expand its impact.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |